NewsRoom Articles - Page 71 of 144 - PsychedelicNewsWire (PNW)

TuesdayOct 19, 2021 12:30 pm

Study Finds MDMA-Assisted Psychotherapy Improves Sleep in PTSD Patients

A new study has found that MDMA-assisted psychotherapy may improve sleep in PTSD patients. The study’s findings were reported in the “Journal of Traumatic Stress.” Study author L. Jerome of the MAPS Public Benefit Corporation stated that the researchers were interested in learning whether MDMA-assisted therapy could decrease sleep difficulties in individuals with post-traumatic stress disorder and who suffer from disrupted sleep as a result. Jerome explained that being hypervigilant and having intrusive thoughts made it hard for individuals to get sleep, noting that slumber could also be interrupted by nightmares associated with trauma. In the report, she observed that…

MondayOct 18, 2021 2:00 pm

Another California City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city council of Arcata, California, decriminalized psychedelic substances. The measure, which was approved in a unanimous vote, will make the distribution, growing and possession of entheogenic substances such as ayahuasca and psilocybin among the lowest law-enforcement priorities in the city. This is in addition to calling upon the district attorney of Humboldt County to consider the measure’s intent when deciding whether to prosecute individuals involved in the use of entheogenic fungi and plants. The initiative further states that driving under the influence as well as the manufacturing and commercial sale of psychedelic substances remains prohibited. In an…

FridayOct 15, 2021 11:00 am

Why We Should Change How We View Psychedelic-Assisted Psychotherapy

Research on psychedelics began long before the substances were made illegal in the 1970s. When they were banned, the promising research on the substances ground to a halt — until recently. The current search for alternative and effective treatments for various mental health conditions has renewed interest in these substances, which have been used by different Indigenous communities for centuries. Now, more people are opening up to the idea of psychedelic substances being used in combination with psychotherapy to treat mental health disorders. Psychedelic substances, which are sometimes referred to as hallucinogens, cause hallucinations. Examples of these substances include ayahuasca,…

FridayOct 15, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803

Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials Tryp Therapeutics (CSE: TRYP)…

ThursdayOct 14, 2021 12:15 pm

Official Tells Legislators That VA Is Following Psychedelics Studies for Veterans

During a recent Congressional hearing, Rep. Colin Allred revealed that the Department of Veterans Affairs (“VA”) has closely been following studies on the therapeutic benefits of psychedelic substances such as MDMA for veterans. The meeting, which was held last month before the House Veterans’ Affairs Committee, focused on innovative approaches to deal with suicide prevention in veterans. Officials had asked for an update on the study evaluating the use of psychedelic substances for the treatment of PTSD in military veterans, noting that there were good results from prior research on how psychedelic substances could help alleviate the mental health struggles…

WednesdayOct 13, 2021 2:45 pm

Seattle Decriminalizes Psychedelics, Becomes Largest American City to Do So

At the start of this week, the city council of Seattle approved a measure to decriminalize non-commercial activity of psychedelics, which includes the sharing and cultivation of substances such as mescaline that haven’t been derived from peyote, ibogaine, ayahuasca and magic mushrooms. This resolution extends the city’s already existing policy to not prosecute or arrest individuals for drug possession and protect the sharing and growing of psychedelic fungi and plants for personal growth, healing, spiritual or religious practices. The measure, which was approved unanimously, stipulates that the arrest or prosecution of any person engaging in entheogen-related activities should be one…

TuesdayOct 12, 2021 2:15 pm

New Hampshire’s Youngest Legislator Calls for Psilocybin Decriminalization

The New Hampshire state legislature is presently under Republican control, which has made it harder for legislators to end marijuana prohibition and establish a regulated sales system. Despite this, Rep. Tony Labranche, one of the youngest state lawmakers in the United States, is calling for the decriminalization of psilocybin and all illicit substances. During an interview last week, the representative spoke about his plans to end the criminalization of individuals who possess or use psilocybin mushrooms in addition to generally decriminalizing the possession of controlled substances. He stated that it was the right thing to do because any individual who…

TuesdayOct 12, 2021 12:50 pm

Delic Holdings (CSE: DELC) (OTCQB: DELCF) Reports Second Quarter Financial Results; Sets Up Business Pillars for Continued Growth

Delic Holdings Corp. (the “company” or “Delic”) reported Q2 revenues of $149,290 while realizing a strong gross profit margin of 87% The company has recently broadened its business verticals through the acquisition of Homestead, a psychedelic media distributor, and Ketamine Infusion Centers LLC, one of the largest chains of ketamine clinics in the U.S. Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has recently published its second quarter results for the 2021 fiscal year. The company reported Q2 revenues of $149,290. Delic also reported second quarter gross profits…

MondayOct 11, 2021 12:45 pm

Elon Musk Acknowledges Potential of Psychedelic Substances at CodeCon

During an interview at CodeCon 21, Elon Musk stated that individuals should be open to psychedelic substances. The tech-development event was hosted by Field Trip Health’s executive chairman, Ronan Levy, who asked Musk about whether he supported the use of psychedelic substances for therapeutic purposes. Levy asked Musk about the role psychedelics could play in addressing some of the society’s destructive tendencies, with Musk replying that while most of individuals who were making laws currently were from a different era, there would be greater receptivity to the substances’ benefits as a new generation got into political power. Field Trip Health…

FridayOct 08, 2021 1:49 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

Tryp Therapeutics recently launched a new website with updated resources to be featured on the site Over the next few weeks, the company will share key resources that will be the standout features of the new website Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050